Table 6 LS-SBA - overall survival by prognostic factors (only patient who received first line chemotherapy)

Gender

Male

16/24

57.1 (35.7 – 78.5)

1.06 (0.53 – 2.11)

0.869

Female

17/22

64.6 (43.4 – 85.8)

-

Primary tumour

Duodenum

26/34

56.5 (38.5 – 74.5)

-

(0.130)

Jejunum

5/7

71.4 (37.9 – 100)

0.55 (0.21 – 1.45)

0.224

Ileum

2/5

75.0 (32.5 – 100)

0.27 (0.06 – 1.17)

0.080

Disease status

Locally Advanced

9/13

67.7 (41.4 – 94.0)

-

Metastatic

22/27

51.6 (31.8 – 71.4)

1.99 (0.90 - 4.42)

0.089

Chemo 1^ST line

Doublet

11/18

52.6 (28.5 – 76.7)

-

Triplet

19/23

64.8 (43.6 – 86.0)

1.67 (0.78 – 3.55)

0.185

Chemo 2^nd line

No

18/17

27.9 (8.1 – 47.7)

-

Yes

19/19

31.6 (10.6 – 52.6)

1.17 (0.61 – 2.24)

0.633

Small Bowel Obstruction

None

21/28

55.3 (35.3 – 75.3)

-

Present

4/8

51.4 (11.4 – 91.4)

0.55 (0.19 – 1.61)

0.274

Weight loss

None

13/23

49.4 (25.1 – 73.7)

-

Present

12/13

61.5 (35.0 – 88.0)

1.11 (0.50 – 2.45)

0.803

CEA at baseline

Normal

5/9

66.7 (35.9 - 97.5)

-

Abnormal

23/27

52.2 (32.4 – 72.0)

3.15 (1.15 – 8.60)

0.025

Hemoglobin

Normal

8/10

90.0 (71.4 – 100)

-

Abnormal

22/29

46.2 (26.6 – 65.8)

1.51 (0.67 – 3.43)

0.323

Albumin

Normal

15/22

80.4 (63.2 – 97.6)

-

Abnormal

15/17

32.1 (9.2 – 55.0)

2.15 (1.03 – 4.46)

0.041

LDH

Normal

13/18

63.6 (39.9 – 87.3)

-

Abnormal

13/16

53.3 (28.0 – 78.6)

1.31 (0.59 – 2.87)

0.507

Alk.Ph

Normal

16/23

70.5 (50.3 – 90.7)

-

Abnormal

14/16

43.8 (19.5 – 68.1)

1.45 (0.70 – 2.99)

0.320

ALT

Normal

23/30

63.4 (45.2 – 81.6)

-

Abnormal

6/8

31.3 (0 – 66.2)

1.96 (0.77 – 4.96)

0.156

Platelets

Normal

15/24

73.4 (55.0 – 91.8)

-

Abnormal

16/17

38.0 (14.1 – 61.9)

2.85 (1.34 – 6.08)

0.007